Shares of OvaScience Inc. (NASDAQ:OVAS) traded down 5.8% on Thursday . The stock traded as low as $5.12 and last traded at $5.16, with a volume of 144,221 shares trading hands. The stock had previously closed at $5.48.

Several analysts have recently weighed in on the stock. Credit Suisse Group AG reaffirmed a “sell” rating on shares of OvaScience in a research note on Tuesday, July 12th. Leerink Swann reaffirmed a “hold” rating and set a $7.00 price target (up previously from $6.00) on shares of OvaScience in a research note on Sunday, May 8th. Finally, Oppenheimer Holdings Inc. reaffirmed a “hold” rating on shares of OvaScience in a research note on Monday, April 25th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. OvaScience presently has a consensus rating of “Hold” and a consensus price target of $12.37.

The firm’s market capitalization is $141.29 million. The company has a 50-day moving average price of $5.38 and a 200 day moving average price of $7.17.

OvaScience (NASDAQ:OVAS) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.80) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.72) by $0.08. The business had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.14 million. The company’s revenue was up 630.0% compared to the same quarter last year. During the same period last year, the firm posted ($0.65) EPS. On average, analysts forecast that OvaScience Inc. will post ($3.14) EPS for the current fiscal year.

In other news, Director Richard Aldrich purchased 20,000 shares of the company’s stock in a transaction dated Wednesday, May 11th. The stock was acquired at an average price of $7.64 per share, with a total value of $152,800.00. Following the purchase, the director now directly owns 604,185 shares in the company, valued at approximately $4,615,973.40. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Michelle Dipp purchased 425,000 shares of the company’s stock in a transaction dated Wednesday, June 1st. The stock was purchased at an average cost of $7.00 per share, with a total value of $2,975,000.00. Following the purchase, the chief executive officer now owns 971,921 shares in the company, valued at $6,803,447. The disclosure for this purchase can be found here.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.